PharmaPoint: Human Immunodeficiency Virus (HIV) – Global Drug Forecast and Market Analysis to 2025

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline’s (GSK’s) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science's Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level of convenience.

GlobalData projects the global HIV marketplace — which, for the purposes of this report, comprises nine major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) — to experience modest growth during the forecast period. This growth will be driven primarily by the highly anticipated arrivals of novel integrase inhibitor (INI-) and protease inhibitor (PI-) based STRs, which include ViiV Healthcare’s dolutegravir/lamivudine, ViiV’s and Janssen’s dolutegravir/rilpivirine, Gilead’s bictegravir/emtricitabine/tenofovir alafenamide fumarate (TAF), Gilead’s and Janssen’s darunavir/cobicistat/emtricitabine/TAF, and ViiV’s long-acting injectable formulation composed of cabotegravir/rilpivirine. Nevertheless, looming patent expiries of high-grossing branded drugs in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with compulsory licensing and generic erosion in Brazil and China, are expected to curtail market growth.

Key Questions Answered
How will the HIV market landscape in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) change from 2015–2025?
What are the most promising late-stage pipeline drugs in HIV?
How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
What are the remaining unmet needs in HIV treatment management?
What drivers and barriers will affect HIV therapeutics sales in the 9MM over the forecast period?

Scope

Overview of HIV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

Topline HIV market revenue from 2015–2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.

Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting HIV therapeutics sales in the 9MM.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

Analysis of the current and future market competition in the global HIV therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global HIV therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HIV therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Gilead Sciences
ViiV Healthcare
Merck & Co.
Janssen (Johnson & Johnson)
Bristol-Myers Squibb
TaiMed Biologics*
Cytodyn*
*Denotes a company without currently marketed HIV therapeutics

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Human Immunodeficiency Virus (HIV): Executive Summary

2.1 HIV Market Will Experience Modest Growth During the Forecast Period

2.2 Companies Leverage Partnerships to Develop New STRs and Fixed-Dose Combinations to Capture HIV Market Share

2.3 While HIV Therapies Continue to Raise the Bar on Efficacy, Safety, and Convenience, Unmet Needs Persist

2.4 Even in the Face of Strong Marketed and Pipeline Products, Opportunities Still Exist for Current and Future Players to Impact the HIV Marketplace

2.5 Novel STRs and FDCs With Improved Efficacy and Safety, and a Decreased Pill Burden, Are Expected to Dominate the Future HIV Treatment Landscape

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology

4.1.1 The Viral Lifecycle

4.2 Pathophysiology

4.3 Staging and Symptoms

4.3.1 Acute Infection

4.3.2 Chronic Infection

4.3.3 Advanced Infection (AIDS)

4.4 Prognosis

4.5 Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global Trends

5.3.1 US

5.3.2 5EU

5.3.3 Japan, Brazil, and China

5.4 Forecast Methodology

5.4.1 Sources Used

5.4.2 Forecast Assumptions and Methods

5.4.3 Sources Not Used

5.5 Epidemiological Forecast for HIV in the 8MM (2015–2025)

5.5.1 Total Prevalent Cases of HIV

5.5.2 Diagnosed Prevalent Cases of HIV

5.5.3 Age-Specific Diagnosed Prevalent Cases of HIV

5.5.4 Sex-Specific Diagnosed Prevalent Cases of HIV

5.5.5 Age-Standardized Diagnosed Prevalence of HIV

5.5.6 Diagnosed Prevalent Cases of HIV Treated with Antiretroviral Therapy

5.5.7 Diagnosed Prevalent Cases of HIV with Hepatitis B Virus Co-infection

5.5.8 Diagnosed Prevalent Cases of HIV with Hepatitis C Virus Co-infection

5.6 Epidemiological Forecast for HIV in Japan (2015–2025)

5.6.1 20-Year Diagnosed Prevalent Cases of HIV

5.6.2 Age-Specific 20-Year Diagnosed Prevalent Cases of HIV

5.6.3 Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV

5.6.4 Age-Standardized 20-Year Diagnosed Prevalence of HIV

5.6.5 20-Year Diagnosed Prevalent Cases of HIV Treated with Antiretroviral Therapy

5.6.6 20-Year Diagnosed Prevalent Cases of HIV with Hepatitis B Virus Co-infection

5.6.7 20-Year Diagnosed Prevalent Cases of HIV with Hepatitis C Virus Co-infection

5.7 Discussion

5.7.1 Epidemiological Forecast Insight

5.7.2 Limitations of Analysis

5.7.3 Strengths of Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.1.1 Screening and Diagnosis

6.1.2 Treatment Guidelines and Leading Prescribed Drugs

6.1.3 Clinical Practice

6.2 US

6.2.1 Screening and Diagnosis

6.2.2 Clinical Practice

6.3 5EU

6.3.1 Screening and Diagnosis

6.3.2 Clinical Practice

6.4 Japan

6.4.1 Screening and Diagnosis

6.4.2 Clinical Practice

6.5 Brazil

6.5.1 Screening and Diagnosis

6.5.2 Clinical Practice

6.6 China

6.6.1 Screening and Diagnosis

6.6.2 Clinical Practice

7 Competitive Assessment

7.1 Overview

7.2 Product Profiles – Major Brands, Single-Tablet Regimens

7.2.1 Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate)

7.2.2 Stribild (cobicistat/elvitegravir/emtricitabine/TDF)

7.2.3 Genvoya (cobicistat/elvitegravir/emtricitabine/TAF)

7.2.4 Triumeq (abacavir/dolutegravir/lamivudine)

7.2.5 Complera (emtricitabine/rilpivirine/TDF)

7.2.6 Odefsey (emtricitabine/rilpivirine/TAF)

7.3 Product Profiles – Major Brands, Fixed-Dose NRTI Backbones

7.3.1 Truvada (emtricitabine/TDF)

7.3.2 Descovy (emtricitabine/TAF)

7.4 Product Profiles – Major Brands, Integrase Inhibitors

7.4.1 Tivicay (dolutegravir)

7.4.2 Isentress (raltegravir)

7.5 Product Profiles – Major Brands, Protease Inhibitors

7.5.1 Prezcobix (darunavir/cobicistat)

7.5.2 Evotaz (atazanavir/cobicistat)

7.6 Other Approved Drugs

7.6.1 Overview

8 Unmet Needs Assessment and Opportunity Analysis

8.1 Overview

8.2 Long-Acting Regimens that Require Less-Frequent Administration

8.2.1 Unmet Need

8.2.2 Gap Analysis

8.2.3 Opportunity

8.3 Enhanced Public Awareness Initiatives Focused on Minimizing the Stigma Associated with HIV Infection

8.3.1 Unmet Need

8.3.2 Gap Analysis

8.3.3 Opportunity

8.4 Improved Physician Education Tools That Emphasize the Importance of Early Testing and Diagnosis

8.4.1 Unmet Need

8.4.2 Gap Analysis

8.4.3 Opportunity

8.5 Safe and Efficacious Therapies for Patients with Drug-Resistant HIV Strains

8.5.1 Unmet Need

8.5.2 Gap Analysis

8.5.3 Opportunity

8.6 Therapies with Improved Safety and Tolerability Profiles

8.6.1 Unmet Need

8.6.2 Gap Analysis

8.6.3 Opportunity

8.7 Progress Towards a Functional Cure

8.7.1 Unmet Need

8.7.2 Gap Analysis

8.7.3 Opportunity

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.2.1 Bictegravir/Emtricitabine/TAF

9.2.2 Dolutegravir/Lamivudine

9.2.3 Cobicistat/Darunavir/Emtricitabine/TAF

9.2.4 Doravirine/Lamivudine/TDF

9.2.5 Dolutegravir/Rilpivirine

9.2.6 Cabotegravir/Rilpivirine

9.2.7 Fostemsavir

9.2.8 Ibalizumab

9.2.9 PRO-140

9.3 Other Drugs in Clinical Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Profiles

10.3.1 Gilead Sciences

10.3.2 ViiV Healthcare

10.3.3 Janssen

10.3.4 Merck & Co.

10.3.5 Bristol-Myers Squibb

10.3.6 Minor and Emerging Players

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

11.5 Brazil

11.5.1 Forecast

11.5.2 Key Events

11.5.3 Drivers and Barriers

11.6 China

11.6.1 Forecast

11.6.2 Key Events

11.6.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.4 Forecasting Methodology

12.4.1 Total and Diagnosed Prevalent Cases of HIV (8MM)

12.4.2 20-Year Diagnosed Prevalent Cases of HIV (Japan)

12.4.3 Diagnosed Prevalent Cases of HIV Treated with ART

12.4.4 Drugs Included in Each Therapeutic Class

12.4.5 Launch and Patent Expiry Dates

12.4.6 General Pricing Assumptions

12.4.7 Individual Drug Assumptions

12.4.8 Generic Erosion

12.4.9 Pricing of Pipeline Agents

12.5 Primary Research – KOLs and Payers Interviewed for this Report

12.5.1 KOLs

12.5.2 Payers

12.6 Primary Research – Prescriber Survey

12.7 About the Authors

12.7.1 Analyst

12.7.2 Therapy Area Director

12.7.3 Epidemiologists

12.7.4 Global Director of Therapy Analysis and Epidemiology

12.7.5 Global Head and EVP of Healthcare Operations and Strategy

12.8 About GlobalData

12.9 Contact Us

12.10 Disclaimer

Table

Table 1: HIV: Key Metrics in the Nine Major Pharmaceutical Markets

Table 2: CDC and WHO Staging Classification of HIV-1 Infection in Patients ≥6 Years

Table 3: Symptoms of Acute, Chronic, and Advanced Stages of HIV Infection

Table 4: Risk Factors and Comorbidities for HIV

Table 5: 5EU, Total Prevalence of HIV in Men and Women (%), All Ages, Selected Years, 2001–2015

Table 6: 8MM, Sources of HIV Total Prevalence Data

Table 7: 8MM, Sources of HIV Diagnosed Prevalence Data

Table 8: Japan, Sources Used to Forecast the 20-Year Diagnosed Prevalent Cases of HIV in Japan

Table 9: 9MM, Sources Used to Forecast Diagnosed Prevalent Cases of HIV on ART

Table 10: 9MM, Sources Used to Forecast Diagnosed Prevalent Cases of HIV with HBV Co-infection

Table 11: 9MM, Sources Used to Forecast Diagnosed Prevalent Cases of HIV with HCV Co-infection

Table 12: 8MM, Total Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015–2025

Table 13: 8MM, Diagnosed Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015–2025

Table 14: 8MM, Age-Specific Diagnosed Prevalent Cases of HIV, Both Sexes, 2015, Cases (N) and Proportions (Row %)

Table 15: 8MM, Sex-Specific Diagnosed Prevalent Cases of HIV, Both Sexes, 2015 (Row %)

Table 16: 8MM, Diagnosed Prevalent HIV Cases Treated with ART, All Ages, Both Sexes, 2015–2025, Cases (N) and Proportions (%)

Table 17: 8MM, Diagnosed Prevalent HIV Cases with HBV Co-infection, All Ages, Both Sexes, 2015–2025, Cases (N) and Proportions (%)

Table 18: 8MM, Diagnosed Prevalent HIV Cases with HCV Co-infection, All Ages, Both Sexes, 2015–2025, Cases (N) and Proportions (%)

Table 19: Japan, 20-Year Diagnosed Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015–2025

Table 20: Japan, Age-Specific 20-Year Diagnosed Prevalent Cases of HIV, Both Sexes, N, 2015 (Row %)

Table 21: Japan, Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV, All Ages, N, 2015 (Row %)

Table 22: Japan, 20-Year Diagnosed Prevalent HIV Cases Treated with ART, All Ages, Both Sexes 2015–2025, Cases (N) and Proportions (%)

Table 23: Japan, 20-Year Diagnosed Prevalent HIV Cases with HBV Co-infection, All Ages, Both Sexes, 2015–2025, Cases (N) and Proportions (%)

Table 24: Japan, 20-Year Diagnosed Prevalent HIV Cases with HCV Co-infection, All Ages, Both Sexes, 2015–2025, Cases (N) and Proportions (%)

Table 25: Treatment Guidelines for HIV-1 Used in the 9MM

Table 26: Most Commonly Prescribed Drugs for HIV-1 by Class in the 9MM, 2015

Table 27: Most Commonly Prescribed Drugs for HIV-1 by Class in the 9MM, 2016

Table 28: Diagnosis and Treatment of HIV Infection, Country Profile – US

Table 29: Switching of ART Regimens in the US, 2015

Table 30: Diagnosis and Treatment of HIV Infection, Country Profile – 5EU

Table 31: CD4+ Thresholds and Corresponding Recommendations for the Initiation of ART in Asymptomatic Patients in the 5EU

Table 32: Switching of ART Regimens in the 5EU, 2015

Table 33: Diagnosis and Treatment of HIV Infection, Country Profile – Japan

Table 34: Switching of ART Regimens in Japan, 2015

Table 35: Diagnosis and Treatment of HIV Infection, Country Profile – Brazil

Table 36: Switching of ART Regimens in Brazil, 2015

Table 37: Diagnosis and Treatment of HIV Infection, Country Profile – China

Table 38: Switching of ART Regimens in China, 2015

Table 39: Leading Branded Treatments for HIV, 2016

Table 40: Product Profile – Atripla

Table 41: Efficacy of Atripla Compared with Combivir + Sustiva

Table 42: Safety of Atripla – Frequency of AEs Compared with Combivir + Sustiva

Table 43: Atripla SWOT Analysis, 2016

Table 44: Product Profile – Stribild

Table 45: Pivotal Phase III Trials of Stribild in Treatment-Naïve Patients

Table 46: Stribild’s Adverse Reactions – Pooled Results From Two Phase III Clinical Trials

Table 47: Stribild SWOT Analysis, 2016

Table 48: Product Profile – Genvoya

Table 49: Efficacy of Genvoya and Stribild in Studies 104 and 111

Table 50: Adverse Events Associated with Genvoya vs. Stribild Therapy in Two Phase III Clinical Studies

Table 51: Genvoya SWOT Analysis, 2016

Table 52: Product Profile – Triumeq

Table 53: Virologic Efficacy of Triumeq in the Phase III SINGLE Study

Table 54: Triumeq’s Safety – Adverse Reactions Reported at 96 Weeks in the SINGLE Study

Table 55: Triumeq SWOT Analysis, 2016

Table 56: Product Profile – Complera

Table 57: ECHO and THRIVE Studies of the Complera and Atripla Multi-tablet Regimens

Table 58: Complera SWOT Analysis, 2016

Table 59: Product Profile – Odefsey

Table 60: Safety of Odefsey – Frequency of AEs

Table 61: Odefsey SWOT Analysis, 2016

Table 62: Product Profile – Truvada

Table 63: Truvada’s Efficacy – Results of the SWIFT Trial at 48 Weeks

Table 64: Truvada SWOT Analysis, 2016

Table 65: Product Profile – Descovy

Table 66: Safety of Descovy – Frequency of AEs

Table 67: Descovy SWOT Analysis, 2016

Table 68: Product Profile – Tivicay

Table 69: Pivotal Phase III Trials of Tivicay

Table 70: Tivicay’s Safety – Adverse Reactions Reported in the 48-Week SINGLE Study

Table 71: Tivicay SWOT Analysis, 2016

Table 72: Product Profile – Isentress

Table 73: Percentage of Patients with HIV-1 RNA Levels <50 Copies/mL from the SMARTMRK Study

Table 74: Isentress’ Safety – Adverse Reactions Reported in the SMARTMRK Study

Table 75: Isentress SWOT Analysis, 2016

Table 76: Product Profile – Prezcobix

Table 77: Efficacy of Prezcobix in the Phase III Trial

Table 78: Prezcobix SWOT Analysis, 2016

Table 79: Product Profile – Evotaz

Table 80: Efficacy of BMS’ Evotaz in the Phase III Study

Table 81: Evotaz SWOT Analysis, 2016

Table 82: Other Approved HIV Drugs

Table 83: Unmet Need and Opportunity in HIV

Table 84: Key Late-Stage Pipeline Agents for HIV Therapeutics, 2016

Table 85: Comparison of Therapeutic Classes in Late-Stage Development for HIV, 2015–2025

Table 86: Product Profile – Bictegravir/Emtricitabine/TAF

Table 87: Gilead’s Bictegravir/Emtricitabine/TAF – Phase III Clinical Trials

Table 88: Bictegravir/Emtricitabine/TAF SWOT Analysis, 2016

Table 89: Product Profile – Dolutegravir/Lamivudine

Table 90: ViiV’s Dolutegravir/Lamivudine – Phase III Clinical Trials

Table 91: Dolutegravir/Lamivudine Safety – Adverse Reactions Reported at 24 Weeks – PADDLE Study

Table 92: Dolutegravir/Lamivudine SWOT Analysis, 2016

Table 93: Product Profile – Cobicistat/Darunavir/Emtricitabine/TAF

Table 94: Janssen’s Cobicistat/Darunavir/Emtricitabine/TAF – Phase III Clinical Trials

Table 95: Cobicistat/Darunavir/Emtricitabine/TAF SWOT Analysis, 2016

Table 96: Product Profile – Doravirine/Lamivudine/TDF

Table 97: Efficacy Results of a Phase II Dose-Ranging Study of Doravirine Compared with a Standard Dose of Efavirenz

Table 98: Doravirine/Lamivudine/TDF SWOT Analysis, 2016

Table 99: Product Profile – Dolutegravir/Rilpivirine

Table 100: Tivicay’s Safety – Adverse Reactions Reported in the 48-Week SINGLE Study

Table 101: Dolutegravir/Rilpivirine SWOT Analysis, 2016

Table 102: Product Profile – Cabotegravir/Rilpivirine

Table 103: Cabotegravir/Rilpivirine SWOT Analysis, 2016

Table 104: Product Profile – Fostemsavir

Table 105: Fostemsavir SWOT Analysis, 2016

Table 106: Product Profile – Ibalizumab

Table 107: TaiMed’s and Theratechnologies’ Ibalizumab – Phase IIb Clinical Trial Outcomes

Table 108: Ibalizumab SWOT Analysis, 2016

Table 109: Product Profile – PRO-140

Table 110: PRO-140 SWOT Analysis, 2016

Table 111: Other Drugs in Phase II of Clinical Development for HIV, 2016

Table 112: Key Companies in the HIV Market in the 9MM, 2016

Table 113: Gilead Sciences’ HIV Portfolio Assessment, 2016

Table 114: ViiV Healthcare’s HIV Portfolio Assessment, 2016

Table 115: Janssen’s HIV Portfolio Assessment, 2016

Table 116: Merck & Co.’s HIV Portfolio Assessment, 2016

Table 117: BMS’ HIV Portfolio Assessment, 2016

Table 118: Global (9MM) Sales Forecasts ($m) for HIV, 2015–2025

Table 119: HIV Therapeutics Market – Global Drivers and Barriers, 2015–2025

Table 120: Sales Forecasts ($m) for HIV in the US, 2015–2025

Table 121: Key Events Impacting Sales for HIV Therapeutics in the US, 2015–2025

Table 122: HIV Therapeutics Market – Drivers and Barriers in the US, 2015‒2025

Table 123: Number of People Living with HIV Who Received ART in the 5EU, and Sales of HIV Therapeutics ($m), 2015

Table 124: Sales Forecasts ($m) for HIV in the 5EU, 2015–2025

Table 125: Key Events Impacting Sales for HIV in the 5EU, 2015–2025

Table 126: HIV Therapeutics Market – Drivers and Barriers in the 5EU, 2015‒2025

Table 127: Sales Forecasts ($m) for HIV in Japan, 2015–2025

Table 128: Key Events Impacting Sales for HIV Therapeutics in Japan, 2015–2025

Table 129: Sales Forecasts ($m) for HIV in Brazil, 2015–2025

Table 130: Key Events Impacting Sales for HIV Therapeutics in Brazil, 2015–2025

Table 131: HIV Therapeutics Market – Drivers and Barriers in Brazil, 2015‒2025

Table 132: Sales Forecasts ($m) for HIV in China, 2015–2025

Table 133: Key Events Impacting Sales of HIV Therapeutics in China, 2015–2025

Table 134: HIV Therapeutics Market – Drivers and Barriers in China, 2015‒2025

Table 135: Key Historical and Projected Launch Dates for HIV Therapeutics Across the 9MM

Table 136: Patent Expiry Dates for HIV Therapeutics Across the 9MM

Table 137: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global (9MM) Sales for HIV by Country/Region, 2015 and 2025

Figure 2: Company Portfolio Gap Analysis in HIV, 2015–2025

Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in HIV, 2015–2025

Figure 4: Cartoon Depicting the HIV Lifecycle

Figure 5: Global Overview of HIV, Men and Women, All Ages, 1990–2015

Figure 6: 8MM, Total Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015–2025

Figure 7: 8MM, Diagnosed Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015–2025

Figure 8: 8MM, Age-Specific Diagnosed Prevalent Cases of HIV, Both Sexes, N, Select Years, 2015–2025

Figure 9: 8MM, Sex-Specific Diagnosed Prevalent Cases of HIV, All Ages, N, Select Years, 2015–2025

Figure 10: 8MM, Age-Standardized Diagnosed Prevalence of HIV (%), All Ages, by Sex, 2015

Figure 11: Japan, 20-Year Diagnosed Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015–2025

Figure 12: Japan, Age-Standardized 20-Year Diagnosed Prevalence of HIV (%), All Ages, by Sex, 2015

Figure 13: HIV Disease Management Flowchart

Figure 14: HIV – Phase III Pipeline, 2016

Figure 15: Competitive Assessment of Late-Stage Pipeline Agents in HIV, 2015–2025

Figure 16: Company Portfolio Gap Analysis in HIV, 2015–2025

Figure 17: Global (9MM) Sales for HIV by Country/Region, 2015 and 2025

Figure 18: Global (9MM) Sales for HIV by Drug Class, 2015 and 2025

Figure 19: Sales for HIV by Drug Class in the US, 2015 and 2025

Figure 20: Sales for HIV by Drug Class in the 5EU, 2015 and 2025

Figure 21: Sales for HIV by Drug Class in Japan, 2015 and 2025

Figure 22: Sales for HIV by Drug Class in Brazil, 2015 and 2025

Figure 23: Sales for HIV by Drug Class in China, 2015 and 2025

Frequently asked questions

PharmaPoint: Human Immunodeficiency Virus (HIV) – Global Drug Forecast and Market Analysis to 2025 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

PharmaPoint: Human Immunodeficiency Virus (HIV) – Global Drug Forecast and Market Analysis to 2025 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at PharmaPoint: Human Immunodeficiency Virus (HIV) – Global Drug Forecast and Market Analysis to 2025 in real time.

  • Access a live PharmaPoint: Human Immunodeficiency Virus (HIV) – Global Drug Forecast and Market Analysis to 2025 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.